UNIQUE EXPERTISE
Headquartered in Reykjavik, Iceland, deCODE is a global leader in analyzing and understanding the human genome. Using our unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer.
UNIQUE CAPABILITIES
We operate the most productive human gene discovery engine in the world, employing our discoveries to identify genetic variations associated with human disease.
OUR PUBLICATIONS
We regularly publish our discoveries in major, peer-reviewed journals, enabling others to further validate and expand upon our findings.
NEWS
deCODE and Roche Announce Mapping of Gene Linked to Rheumatoid Arthritis
The discovery points the way to new predictive diagnostic markers and drug targets for RA Reykjavik, ICELAND and Basel, SWITZERLAND, November 29, 2001 — deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) and Roche today announced that deCODE scientists have mapped the first...
deCODE Locates First Gene Linked to Late-onset Parkinson’s Disease
Reykjavik, ICELAND, October 23, 2001 ¾ Scientists at deCODE genetics (Nasdaq/Nasdaq Europe:DCGN) have successfully mapped a gene contributing to late-onset Parkinson’s disease, the first genetic factor ever mapped for the most common form of the disease. The company...
Award by the American Society of Human Genetics
At its Annual meeting in October 2017 in Orlando, the American Society of Human Genetics (ASHG), presented Dr. Kári Stefánsson, founder and CEO of deCODE genetics, with the William Allan Award. The award, the top prize given by the society, recognizes a scientist for substantial and far-reaching scientific contributions to human genetics. The ASHG has distributed video footage from the award ceremony. The introduction is given by Professor Mark Daly of Harvard University.